Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Immatics biotechnologies

Request full access

Combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets

Tübingen, GermanyFounded 2000Biotech & Life Sciences

At a glance

Status
Listed
Listing
Public via SPAC 2020

Immatics biotechnologies in the Tübingen ecosystem

Live from Dealroom

The Immatics biotechnologies office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

17 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • EMBL Ventures
  • 3i Group
  • Wellington Partners
  • L-Bank
  • Vinci Capital
  • Grazia Equity

Series B and later11 investors entered at this stage

  • Bristol-Myers Squibb
  • DH Capital
  • MIG Capital
  • b2venture
  • KfW
  • dievini Hopp Biotech holding
  • Celgene
  • Swisscom Ventures
  • AT Impf GmbH
  • Amgen
  • Dezima Pharma
Employees mapped 649 incl. 14 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 14 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia 4 alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$272M

204 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Immatics biotechnologies on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.